Bispecific Antibodies Unleashed

Advances in disease biology have spurred the rapid development of bispecific antibodies (BsAbs), synthetic proteins capable of targeting two distinct epitopes from different antigens. This bispecific functionality holds immense therapeutic potential, extending their applicability to a wide range of therapies. Originally developed for cancer treatment, BsAbs now show promise in imaging, diagnostics, disease prevention, and treatment. Several BsAbs have already gained regulatory approval, with hundreds more in development.

This white paper delves into the predominant formats and mechanisms of action of bispecific antibodies, the most common techniques for their transient production, and the key aspects of their process development. Additionally, we will highlight the advantages of partnering with a CDMO that offers world-class services from discovery to production, ensuring the success of your BsAbs by delivering precise immunotherapy solutions and avoiding costly regulatory mistakes. Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.